Covishield builds more antibodies than Covaxin: Preliminary studies
NEW DELHI:
A preliminary study by Coronavirus vaccine-induced Antibody Titre (COVAT) involving health care workers has stated that Covishield produces more antibodies than Covaxin.
It said that both vaccines– Covishield and Covaxin– elicited a good response after two doses, but seropositivity rate and median anti-spike antibody were significantly higher in Covishield.
The study is a preprint and has not been peer-reviewed, and therefore should not be used to guide clinical practice.
“Amongst the 552 healthcare worker (HCW) (325 Male, 227 Female), 456 and 96 received the first dose of Covishield and Covaxin, respectively. Overall, 79.3 per cent showed seropositivity after the first dose. Responder rate and median (IQR) rise in anti-spike antibody were significantly higher in Covishield vs Covaxin recipient (86.8 vs 43.8 per cent),” the study said.
The study involved those healthcare workers who have been administered either of the two vaccines Covishield and Covaxin and is with or without a past history of SARS-CoV-2 infection.
“This ongoing, Pan-India, Cross-sectional, Coronavirus Vaccine-induced Antibody Titre (COVAT) study is being conducted amongst HCW, with or without a past history of SARS-CoV-2 infection. SARS-CoV-2 anti-spike binding antibody is being assessed quantitatively at four-time points between 21 days or more after the first dose to six months after the second dose,” the study said.
However, the conclusion of the study said that both the vaccines have shown elicited good immune response.
“While both vaccines elicited immune response, seropositivity rates to anti-spike antibody were significantly higher in Covishield recipient compared to Covaxin after the first dose. Ongoing COVAT study will further enlighten the immune response between two vaccines after the second dose,” it said.
With inputs from ANI
(Edited by Ridhika Joshi)
TNT-The Northeast Today is now on WhatsApp. CLICK HERE to receive more updates on your phone
ALSO WATCH:
